Chardan Healthcare Acquisition Corp. (CHAC) announced this evening that it has entered into a business combination agreement with BiomX Ltd. (“BiomX”). BiomX is a preclinical stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
The company’s pipeline includes preclinical candidates for acne-prone skin, inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and colorectal cancer (CRC). BiomX’s product for acne-prone skin is anticipated to begin clinical testing by the end of 2019. The combined company will continue to be led by BiomX’s experienced management team headed by Chief Executive Officer Jonathan Solomon.
CHAC has entered into a mix of commitments including purchase and sale, backstop, and voting agreements with BiomX and with investors — including OrbiMed, RTW Investment, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Takeda Ventures, Inc., Seventure Partners’ Health for Life Capital I, SBI Japan-Israel Innovation Fund, as well as RM Global Partners (RMGP) BioPharma Investment Fund — so that the $50 million minimum closing condition for the transaction has been satisfied prior to today’s announcement.
Post-closing, Mr. Solomon and three current BiomX directors will join Mr. Jonas Grossman and Dr. Gbola Amusa from CHAC, on the seven-person board of directors. An additional board member will be designated by BiomX.
Conference Call Scheduled
CHAC will host a conference call to discuss the proposed business combination with the investment community on July 17, 2019 at 8:30 AM EDT.
(877) 705-6003 toll-free in the U.S.
(201) 493-6725 internationally
The conference ID number is 13692693.
The conference call webcast will be available at http://public.viavid.com/index.php?id=135425.
Quick takes: There’s not a lot to go on just yet since none of the agreements or presentation were filed as of this evening, just the press release was put forth. However, post-conference call and filings, we will update this post with some additional analysis.
TRANSACTION DETAILS
CHAC will issue 16.625 million shares and vested securities to current security holders of BiomX.
Earnout
BiomX shareholders will be entitled to receive earn-out consideration of an additional six million CHAC shares.
- 2.0 million shares if the share price exceeds $16.50 by fiscal year 2021
- 2.0 million shares if the share price exceeds $22.75 by fiscal year 2023
- 2.0 million shares if the share price exceeds $29.00 by fiscal year 2025
Board Composition
- Post-closing, BiomX CEO, Mr. Joseph Solomon, and three current BiomX directors will join Mr. Grossman and Dr. Amusa, from CHAC, on the seven-person board of directors. An additional board member will be designated by BiomX.
ADVISORS
- Chardan is acting as CHAC’s M&A and capital markets advisor.
- Cantor is acting as capital markets advisor to BiomX.
- Loeb & Loeb LLP and Meitar Liquornik Geva Leshem Tal are representing CHAC.
- Goodwin Procter LLP, Mayer Brown LLP and ZAG-S&W Zysman Aharoni Gayer & Co are representing BiomX.
A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...
At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...
Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....
At the SPAC of Dawn In a trading session that may find itself built around the release of Fed minutes at 2 pm ET this afternoon, a pair of SPAC targets have added their own fresh information to the mix. Enterprise AI firm Fusemachines, which has a pending combination with CSLM (OTC:CSLMF), put out a...
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...